Remestemcel-L allogeneic bone marrow-derived mesenchymal stem cell product to treat medically refractory Crohn's colitis: preliminary phase IB/IIA study

Br J Surg. 2022 Jul 15;109(8):653-655. doi: 10.1093/bjs/znac078.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II

MeSH terms

  • Biological Products
  • Bone Marrow
  • Colitis*
  • Crohn Disease* / therapy
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Mesenchymal Stem Cell Transplantation*
  • Mesenchymal Stem Cells*

Substances

  • Biological Products
  • remestemcel-l